Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 339

1.

Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression.

Calabrese J, Rajagopalan K, Ng-Mak D, Bacci ED, Wyrwich K, Pikalov A, Loebel A.

Int Clin Psychopharmacol. 2015 Dec 29. [Epub ahead of print]

PMID:
26717493
2.

Lurasidone in Adults with Schizophrenia in the UK: A Cost Consequence Analysis Considering Cost Implications of Improved Efficacy and Safety.

Rajagopalan K, Trueman D, Crowe L, Patel P, Loebel A.

Value Health. 2015 Nov;18(7):A408. doi: 10.1016/j.jval.2015.09.967. Epub 2015 Oct 20. No abstract available.

PMID:
26532300
3.

Cost-Utility and Budget Impact Analyses Comparing Lurasidone with Aripiprazole in Adults with Schizophrenia in Scotland.

Rajagopalan K, Trueman D, Crowe L, Patel P, Loebel A.

Value Health. 2015 Nov;18(7):A408-9. doi: 10.1016/j.jval.2015.09.968. Epub 2015 Oct 20. No abstract available.

PMID:
26532299
4.

Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study.

Loebel A, Siu C, Rajagopalan K, Pikalov A, Cucchiaro J, Ketter TA.

J Affect Disord. 2015 Nov 1;186:376-82. doi: 10.1016/j.jad.2015.07.033. Epub 2015 Aug 5.

5.

Phosphorylation-induced Conformational Ensemble Switching in an Intrinsically Disordered Cancer/Testis Antigen.

He Y, Chen Y, Mooney SM, Rajagopalan K, Bhargava A, Sacho E, Weninger K, Bryan PN, Kulkarni P, Orban J.

J Biol Chem. 2015 Oct 9;290(41):25090-102. doi: 10.1074/jbc.M115.658583. Epub 2015 Aug 4.

PMID:
26242913
6.

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells.

Rajagopalan KN, Egnatchik RA, Calvaruso MA, Wasti AT, Padanad MS, Boroughs LK, Ko B, Hensley CT, Acar M, Hu Z, Jiang L, Pascual JM, Scaglioni PP, DeBerardinis RJ.

Cancer Metab. 2015 Jun 29;3:7. doi: 10.1186/s40170-015-0134-4. eCollection 2015.

7.

Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.

Rajagopalan K, Meyer K, O'Day K, Denno M, Loebel A.

J Med Econ. 2015;18(10):821-7. doi: 10.3111/13696998.2015.1052462. Epub 2015 Jul 27.

PMID:
25985265
8.

Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future.

Rajagopalan K, Govindan R.

J Thorac Dis. 2015 Mar;7(3):217-9. doi: 10.3978/j.issn.2072-1439.2015.01.53. No abstract available.

9.

Chemotherapy advances in locally advanced head and neck cancer.

Georges P, Rajagopalan K, Leon C, Singh P, Ahmad N, Nader K, Kubicek GJ.

World J Clin Oncol. 2014 Dec 10;5(5):966-72. doi: 10.5306/wjco.v5.i5.966. Review.

10.

Structure of the Arabidopsis thaliana TOP2 oligopeptidase.

Wang R, Rajagopalan K, Sadre-Bazzaz K, Moreau M, Klessig DF, Tong L.

Acta Crystallogr F Struct Biol Commun. 2014 May;70(Pt 5):555-9. doi: 10.1107/S2053230X14006128. Epub 2014 Apr 15.

11.

Gold nanoparticles electroporation enhanced polyplex delivery to mammalian cells.

Huang S, Deshmukh H, Rajagopalan KK, Wang S.

Electrophoresis. 2014 Jul;35(12-13):1837-45. doi: 10.1002/elps.201300617.

12.

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

Awad G, Hassan M, Loebel A, Hsu J, Pikalov A, Rajagopalan K.

BMC Psychiatry. 2014 Feb 23;14:53. doi: 10.1186/1471-244X-14-53.

13.

Cancer/testis antigen PAGE4, a regulator of c-Jun transactivation, is phosphorylated by homeodomain-interacting protein kinase 1, a component of the stress-response pathway.

Mooney SM, Qiu R, Kim JJ, Sacho EJ, Rajagopalan K, Johng D, Shiraishi T, Kulkarni P, Weninger KR.

Biochemistry. 2014 Mar 18;53(10):1670-9. doi: 10.1021/bi500013w. Epub 2014 Mar 5.

14.

Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.

Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS.

Int J Chron Obstruct Pulmon Dis. 2013;8:631-9. doi: 10.2147/COPD.S52557. Epub 2013 Dec 5.

15.

The Stress-response protein prostate-associated gene 4, interacts with c-Jun and potentiates its transactivation.

Rajagopalan K, Qiu R, Mooney SM, Rao S, Shiraishi T, Sacho E, Huang H, Shapiro E, Weninger KR, Kulkarni P.

Biochim Biophys Acta. 2014 Feb;1842(2):154-63. doi: 10.1016/j.bbadis.2013.11.014. Epub 2013 Nov 18.

16.

CETN1 is a cancer testis antigen with expression in prostate and pancreatic cancers.

Kim JJ, Rajagopalan K, Hussain B, Williams BH, Kulkarni P, Mooney SM.

Biomark Res. 2013 Jun 13;1(1):22. doi: 10.1186/2050-7771-1-22.

17.

Effect of exchange of the cysteine molybdenum ligand with selenocysteine on the structure and function of the active site in human sulfite oxidase.

Reschke S, Niks D, Wilson H, Sigfridsson KG, Haumann M, Rajagopalan KV, Hille R, Leimk├╝hler S.

Biochemistry. 2013 Nov 19;52(46):8295-303. doi: 10.1021/bi4008512. Epub 2013 Nov 7.

PMID:
24147957
18.

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US.

O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A.

Clinicoecon Outcomes Res. 2013 Sep 13;5:459-70. doi: 10.2147/CEOR.S47990. eCollection 2013.

19.

Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy.

Bollu V, Ejzykowicz F, Rajagopalan K, Karafilidis J, Hay JW.

J Med Econ. 2013 Aug;16(8):1082-8. doi: 10.3111/13696998.2013.815625. Epub 2013 Jun 26.

PMID:
23777224
20.

Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.

Rajagopalan K, O'Day K, Meyer K, Pikalov A, Loebel A.

J Med Econ. 2013 Aug;16(8):987-96. doi: 10.3111/13696998.2013.809353. Epub 2013 Jun 21.

PMID:
23742620
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk